Drug Profile
Kanitinib - KONRUNS Pharmaceutical
Alternative Names: CX1003Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator KONRUNS Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
- 31 Jul 2020 Beijing Konruns Pharmaceutical completes a phase I trial in Solid tumour (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) in China (NCT02916095)
- 27 Apr 2020 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT04093466)